Table 3. Subgroup analysis between CD4⁺CD25⁺ T cell and overall survival.

	cell proportion	Median survival (months)	p	HR*	95%CI
Stage
≤II	≤5%	97.8	0.02	1.00
	>5%	50.9		1.76	1.07, 2.87
>II	≤5%	67.7	0.09
	>5%	34.3		1.91	0.93, 3.93
Molecular subtype
Luminal A	≤5%	108.0	0.46
	>5%	NA		0.73	0.30, 1.79
Luminal B	≤5%	70.8	0.10
	>5%	33.9		5.90	0.64, 54.47
HER2+	≤5%	38.7	0.73
	>5%	16.1		1.23	0.31, 4.85
TNBC	≤5%	NA	0.04
	>5%	26.3		3.59	1.05, 12.29

^*adjusting age, PR, chemotherapy, endocrine-therapy and radiotherapy.